Aiello et al.,3030. Aiello EN, D’Iorio A, Solca F, Torre S, Bonetti R, Scheveger F, et al. Clinimetrics and feasibility of the Italian version of the Frontal Assessment Battery (FAB) in non-demented Parkinson’s disease patients. J Neural Transm (Vienna). 2023;130(5):687-96. https://doi.org/10.1007/s00702-023-02624-7 https://doi.org/10.1007/s00702-023-02624...
|
Europe |
Cross sectional |
73 |
67.0 (8.9) |
22.2 (4.7) |
13.2 (9.2) |
-0.32 |
Baik et al.,3131. Baik K, Kim SM, Jung JH, Lee YH, Chung SJ, Yoo HS, et al. Donepezil for mild cognitive impairment in Parkinson’s disease. Sci Rep. 2021;11(1):4734. https://doi.org/10.1038/s41598-021-84243-4 https://doi.org/10.1038/s41598-021-84243...
|
Asia |
Intervention (Baseline) |
50 |
67.9 (7.1) |
22.4 (4.2) |
20.0 (7.1) |
-0.30 |
Chaudhary et al.,3232. Chaudhary S, Kumaran SS, Kaloiya GS, Goyal V, Sagar R, Kalaivani M, et al. Domain specific cognitive impairment in Parkinson’s patients with mild cognitive impairment. J Clin Neurosci. 2020;75:99-105. https://doi.org/10.1016/j.jocn.2020.03.015 https://doi.org/10.1016/j.jocn.2020.03.0...
|
Asia |
Cross sectional |
64 |
60.0 (6.1) |
23.8 (3.3) |
13.0 (6.5) |
-0.31 |
Flannery et al.,3333. Flannery SL, Jowett T, Garvey A, Cutfield NJ, Machado L. Computerized testing in Parkinson’s disease: Performance deficits in relation to standard clinical measures. J Clin Exp Neuropsychol. 2018;40(10):1062-73. https://doi.org/10.1080/13803395.2018.1485880 https://doi.org/10.1080/13803395.2018.14...
|
Oceania |
Case control |
50 |
68.5 (7.6) |
25.8 (3.8) |
30.3 (13.2) |
-0.50 |
Hendershot et al.,3434. Hendershott TR, Zhu D, Llanes S, Poston KL. Domain-specific accuracy of the Montreal Cognitive Assessment subsections in Parkinson’s disease. Parkinsonism Relat Disord. 2017;38:31-4. https://doi.org/10.1016/j.parkreldis.2017.02.008 https://doi.org/10.1016/j.parkreldis.201...
|
USA |
Cross sectional |
82 |
67.2 (8.4) |
24.7 (4.8) |
35.3 (11.8) |
-0.40 |
Hoops et al.,3535. Hoops S, Nazem S, Siderowf AD, Duda JE, Xie SX, Stern MB, et al. Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson disease. Neurology. 2009;73(21):1738-45. https://doi.org/10.1212/WNL.0b013e3181c34b47 https://doi.org/10.1212/WNL.0b013e3181c3...
|
USA |
Cross sectional |
132 |
65.1 (9.7) |
25.0 (3.8) |
24.6 (11.3) |
-0.24 |
Chen et al.,3636. Chen J, Zhao D, Wang Q, Chen J, Bai C, Li Y, et al. Predictors of cognitive impairment in newly diagnosed Parkinson’s disease with normal cognition at baseline: a 5-year cohort study. Front Aging Neurosci. 2023;15:1142558. https://doi.org/10.3389/fnagi.2023.1142558 https://doi.org/10.3389/fnagi.2023.11425...
|
Multiple sites |
Longitudinal correlation (Baseline) |
232 |
60.3 (9.2) |
28.2 (1.3) |
18.4 (8.4) |
-0.11 |
Kahya et al.,3737. Kahya M, Moon S, Lyons KE, Pahwa R, Akinwuntan AE, Devos H. Pupillary response to cognitive demand in Parkinson’s disease: a pilot study. Front Aging Neurosc. 2018;10:90. https://doi.org/10.3389/fnagi.2018.00090 https://doi.org/10.3389/fnagi.2018.00090...
|
USA |
Case control |
24 |
68.0 (N/A) |
27.58 (1.52) |
31.29 (11.25) |
-0.04 |
Neikrug et al.,3838. Neikrug AB, Maglione JE, Liu L, Natarajan L, Avanzino JA, Corey-Bloom J, et al. Effects of sleep disorders on the non-motor symptoms of Parkinson disease. J Clin Sleep Med. 2013;9(11):1119-29. https://doi.org/10.5664/jcsm.3148 https://doi.org/10.5664/jcsm.3148...
|
USA |
Cross sectional |
80 |
67.4 (8.8) |
24.6 (3.4) |
3.5 (2.3) |
0.08 |
Pimenta et al.,3939. Pimenta M, Moreira D, Nogueira T, Silva C, Pinto EB, Valenca GT, et al. Anxiety independently contributes to severity of freezing of gait in people with Parkinson’s disease. J Neuropsychiatry Clin Neurosci. 2019;31(1):80-5. https://doi.org/10.1176/appi.neuropsych.17090177 https://doi.org/10.1176/appi.neuropsych....
|
Latin + South America |
Cross sectional |
58 |
69.0 (N/A) |
17.2 (4.7) |
32.3 (12.3) |
-0.13 |
Prell et al.,4040. Prell T, Liebermann JD, Mendorf S, Lehmann T, Zipprich HM. Pain coping strategies and their association with quality of life in people with Parkinson’s disease: a cross-sectional study. PLoS One. 2021;16(11):e0257966. https://doi.org/10.1371/journal.pone.0257966 https://doi.org/10.1371/journal.pone.025...
|
Europe |
Cross sectional |
52 |
74.4 (6.6) |
25.0 (3.0) |
29.3 (12.2) |
-0.10 |
Reginold et al.,4141. Reginold W, Armstrong MJ, Duff-Canning S, Lang A, Tang-Wai D, Fox S, et al. The pill questionnaire in a nondemented Parkinson’s disease population. Mov Disord. 2012;27(10):1308-11. https://doi.org/10.1002/mds.25124 https://doi.org/10.1002/mds.25124...
|
Multiple sites |
Cross sectional |
490 |
71.3 (5.2) |
25.6 (3.1) |
27.5 (13.9) |
-0.20 |
Rong et al.,4242. Rong S, Zhang P, He C, Li Y, Li X, Li R, et al. Abnormal neural activity in different frequency bands in parkinson’s disease with mild cognitive impairment. Front Aging Neurosci. 2021;13:709998. https://doi.org/10.3389/fnagi.2021.709998 https://doi.org/10.3389/fnagi.2021.70999...
|
Asia |
Cross sectional |
66 |
65.1 (6.0) |
21.6 (0.54) |
32.3 (1.8) |
-0.35 |
Rucco et al.,4343. Rucco R, Lardone A, Liparoti M, Lopez ET, De Micco R, Tessitore A, et al. Brain networks and cognitive impairment in Parkinson’s disease. Brain Connect. 2022;12(5):465-75. https://doi.org/10.1089/brain.2020.0985 https://doi.org/10.1089/brain.2020.0985...
|
Europe |
Case control |
31 |
65.0 (8.2) |
22.4 (3.3) |
25.0 (9.6) |
-0.01 |
Silverdale et al.,4444. Silverdale MA, Kobylecki C, Kass-Iliyya L, Martinez-Martin P, Lawton M, Cotterill S, et al. A detailed clinical study of pain in 1957 participants with early/moderate Parkinson’s disease. Parkinsonism Relat Disord. 2018;56:27-32. https://doi.org/10.1016/j.parkreldis.2018.06.001 https://doi.org/10.1016/j.parkreldis.201...
|
Europe |
Cross sectional |
1556 |
68.0 (9.5) |
25.1 (3.6) |
26.7 (13.6) |
-0.24 |
Soares et al.,4545. Soares NM, Pereira GM, Dutra ACL, Artigas NR, Krimberg JS, Monticelli BE, et al. Low serum uric acid levels and levodopa-induced dyskinesia in Parkinson’s disease. Arq Neuropsiquiatr. 2023;81(1):40-6. https://doi.org/10.1055/s-0043-1761294 https://doi.org/10.1055/s-0043-1761294...
|
Latin + South America |
Cross sectional |
81 |
63.0 (9.8) |
23.7 (4.8) |
44.8 (15.0) |
-0.22 |
Stern et al.,4646. Stern RB, d’Alencar MS, Uscapi YL, Gubitoso MD, Roque AC, Helene AF, et al. Goalkeeper game: a new assessment tool for prediction of gait performance under complex condition in people with Parkinson’s disease. Front Aging Neurosci. 2020;12:50. https://doi.org/10.3389/fnagi.2020.00050 https://doi.org/10.3389/fnagi.2020.00050...
|
Latin + South America |
Cross sectional |
74 |
67.5 (8.7) |
24.6 (3.0) |
10.0 (8.6) |
-0.10 |
Still et al.,4747. Still A, Hale L, Swain N, Jayakaran P. Self-reported depression and anxiety are correlated with functional disability in Parkinson’s disease. New Zealand Journal of Physiotherapy. 2023;49(1):40-9. https://doi.org/10.15619/nzjp/49.1.06 https://doi.org/10.15619/nzjp/49.1.06...
|
Oceania |
Cross sectional |
19 |
68.8 (6.5) |
26.1 (2.7) |
22.2 (10.8) |
-0.47 |
Tandra et al.,4848. Tandra S, Ramavath B, Kandadai RM, Jabeen SA, Kannan MA, Borgohain R. Functional outcome of bilateral subthalamic nucleus-deep brain stimulation in advanced Parkinson’s disease patients: a prospective study. Ann Indian Acad Neurol. 2020;23(1):54-8. https://doi.org/10.4103/aian.AIAN_357_18 https://doi.org/10.4103/aian.AIAN_357_18...
|
Asia |
Non-randomized intervention (Baseline) |
40 |
55.5 (9.8) |
28.6 (1.8) |
39.7 (10.1) |
-0.44 |
Thomas et al.,4949. Thomas GEC, Leyland LA, Schrag AE, Lees AJ, Acosta-Cabronero J, Weil RS. Brain iron deposition is linked with cognitive severity in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2020;91(4):418-25. https://doi.org/10.1136/jnnp-2019-322042 https://doi.org/10.1136/jnnp-2019-322042...
|
Europe |
Case control |
100 |
64.5 (7.7) |
28.0 (2.0) |
22.6 (11.7) |
-0.11 |